Latest Breaking News On - Puma biotechnology inc - Page 12 : comparemela.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlanh auerbachPuma biotechnology incEuropean commissionCompensation committee of puma board directorsDrug administrationCompensation committeeInducement incentive award planNasdaq listing rulePuma biotechnologyMariann ohanesian

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesPuma biotechnology incEuropean commissionCompensation committee of puma board directorsDrug administrationPuma biotechnologyCompensation committeeInducement incentive award planNasdaq listing rule

Global Chemotherapy Research Report 2023: Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors Markets, 2017-2022, 2022-2027F, 2032F

/PRNewswire/ The "Chemotherapy Global Market Report 2023" report has been added to ResearchAndMarkets.com s offering. The global chemotherapy market is.

United statesEli lillyLaura woodBristol myers squibb companyImprimed incResearch institutesAstrazeneca pharmaceuticalsRoche ltdCelgene corporationTakeda pharmaceutical companySegmentation by serviceAmgen incOffice hours callE st office hours callAstellas pharma incBayer ag

Puma Biotechnology (NASDAQ:PBYI) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI – Free Report) in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. StockNews.com started coverage on shares of […]

United statesMaximof nouguesAlanh auerbachPrudential financial incPuma biotechnology incMackenzie financial corpPanagora asset management incBlackrock incHermes incPuma biotechnology company profileSecurities exchange commissionPuma biotechnologyFree reportBiotechnology trading downGet free reportExchange commission

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cel

LOS ANGELES (BUSINESS WIRE) Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients.

United statesAlanh auerbachDrug administrationEuropean commissionExchange commissionPuma biotechnology incPuma biotechnologyOrphan drug designationChief executive officerInvestigational new drugAnnual report